PLUR Pluri Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1158780 · Fiscal year ends 06/30
Financial factors as of 2026-09-30 (2027Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY10.0%
TTM net income YoY-25.8%
TTM EPS YoY15.7%
Revenue 3-yr CAGR79.1%
Net income 3-yr CAGR—
Margins
Gross margin52.0%
Operating margin-2,341.1%
Net margin-1,943.9%
FCF margin-1,317.8%
EBITDA margin-2,306.0%
Returns
ROE—
ROA-96.8%
ROIC (approx.)—
Asset turnover0.05x
Leverage & solvency
Liabilities / assets167.1%
Debt / equity—
Current ratio0.27x
Interest coverage-36.77x
Cash quality & payout
Operating cash flow / net income0.66x
Accruals ratio-33.0%
Payout ratio—
Capex / revenue35.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2027Q12026-09-30 | 2026Q4*2026-06-30 | 2026Q32026-03-31 | 2026Q22025-12-31 | 2026Q12025-09-30 | 2025Q4*2025-06-30 | 2025Q32025-03-31 | 2025Q22024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $759,000 | $335,000 | $167,000 | $198,000 | $316,000 | $398,000 | $427,000 | $185,000 |
| Cost of revenue | $339,000 | $139,000 | $111,000 | $112,000 | $201,000 | $191,000 | $291,000 | $74,000 |
| Gross profit | $420,000 | $196,000 | $56,000 | $86,000 | $115,000 | $207,000 | $136,000 | $111,000 |
| R&D expense | $13.67M | $3.37M | $3.96M | $3.83M | $3.93M | $3.99M | $3.04M | $2.92M |
| SG&A expense | $2.32M | $2.37M | $2.63M | $2.77M | $2.53M | $2.83M | $2.49M | $2.14M |
| Operating income | -$15.57M | -$5.55M | -$6.54M | -$6.51M | -$6.35M | -$6.62M | -$5.40M | -$4.96M |
| Interest expense | $226,000 | $235,000 | $237,000 | $231,000 | $229,000 | $233,000 | $212,000 | $211,000 |
| Pretax income | -$15.38M | -$6.19M | -$6.18M | -$6.88M | -$6.14M | -$7.77M | -$6.33M | -$3.11M |
| Income tax | $12,000 | -$1,000 | -$8,000 | -$8,000 | -$8,000 | — | — | — |
| Net income | -$10.39M | -$5.88M | -$5.55M | -$6.54M | -$5.85M | -$7.60M | -$6.15M | -$2.96M |
| EBITDA | -$15.44M | -$5.42M | -$6.41M | -$6.38M | -$6.22M | -$6.51M | -$5.33M | -$4.89M |
| EPS (basic) | -0.85 | — | -0.55 | -0.71 | -0.65 | — | -0.94 | -0.53 |
| EPS (diluted) | -0.85 | — | -0.55 | -0.71 | -0.65 | — | -0.94 | -0.53 |
| Weighted avg. shares (diluted) | 12.18M | — | 10.05M | 9.26M | 9.00M | — | 6.56M | 5.55M |
| Balance sheet | ||||||||
| Cash & equivalents | $3.46M | $3.53M | $3.42M | $4.69M | $5.60M | $7.20M | $9.69M | $8.29M |
| Current assets | $8.94M | $8.73M | $10.46M | $13.80M | $16.92M | $22.09M | $27.45M | $22.37M |
| PP&E, net | — | $1.57M | — | $1.72M | $1.76M | $1.82M | $1.59M | $911,000 |
| Goodwill | $3.14M | $3.14M | $3.14M | $3.14M | $3.14M | $3.14M | — | — |
| Intangibles | $2.57M | $2.61M | $2.66M | $2.70M | $2.75M | $2.79M | — | — |
| Total assets | $24.93M | $24.88M | $26.06M | $30.60M | $33.67M | $38.68M | $37.41M | $30.86M |
| Current liabilities | $32.83M | $32.72M | $32.01M | $32.35M | $32.16M | $32.33M | $5.71M | $4.44M |
| Total liabilities | $41.66M | $42.31M | $39.06M | $39.81M | $39.32M | $39.55M | $36.92M | $33.78M |
| Shareholders' equity | -$22.40M | -$23.04M | -$18.60M | -$14.61M | -$11.36M | -$6.84M | -$4.47M | -$8.03M |
| Shares outstanding | 12.61M | 10.82M | 10.43M | 9.98M | 8.16M | 7.89M | 7.78M | 5.57M |
| Cash flow statement | ||||||||
| Operating cash flow | -$4.55M | -$4.44M | -$4.51M | -$5.21M | -$5.43M | -$5.22M | -$4.30M | -$4.63M |
| Capital expenditure | $3,000 | $26,000 | $44,000 | $447,000 | $116,000 | $721,000 | $577,000 | $112,000 |
| Free cash flow | -$4.55M | -$4.47M | -$4.56M | -$5.65M | -$5.54M | -$5.94M | -$4.88M | -$4.74M |
| Investing cash flow | $89,000 | $1.61M | $1.79M | $2.66M | $3.85M | $3.03M | -$4.23M | $8.64M |
| Financing cash flow | $4.43M | $2.82M | $1.38M | — | — | -$435,000 | — | — |
| Depreciation & amortization | $131,000 | $124,000 | $128,000 | $129,000 | $130,000 | $111,000 | $72,000 | $68,000 |
| Stock-based compensation | $238,000 | $476,000 | $395,000 | $763,000 | $1.35M | $838,000 | $463,000 | $256,000 |
Free plan shows the latest 8 periods; Pro shows all 67 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.